Suppr超能文献

在一项基于监测、流行病学和最终结果(SEER)人群的研究中,肿瘤大小对按联合激素受体状态分层的乳腺癌特异性生存的影响。

Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study.

作者信息

Zheng Yi-Zi, Wang Lei, Hu Xin, Shao Zhi-Ming

机构信息

Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

出版信息

Oncotarget. 2015 Sep 8;6(26):22985-95. doi: 10.18632/oncotarget.3945.

Abstract

BACKGROUND & AIMS: The prognostic value of tumor size is variable. We aimed to characterize the interaction between tumor size and hormone receptor (HoR) status to determine breast cancer-specific mortality (BCSM).

METHODS

We used the Surveillance, Epidemiology and End Results (SEER) registry to identify 328, 870 female patients diagnosed with invasive breast cancer from 1990 through 2010. Primary study variables included tumor size, joint HoR status and their corresponding relationship. Kaplan-Meier and adjusted Cox proportional hazards models with interaction terms were utilized.

RESULTS

The multivariable analysis revealed a significant interaction between tumor size and HoR status (P < 0.001). Using tumors 61-70 mm in size as the reference for estrogen receptor-negative (ER-) and progesterone receptor-negative (PR-) disease, the hazard ratio (HR) for BCSM increased with increasing tumor size across nearly all categories. In the ER-positive (ER+) and PR-positive (PR+) group, however, patients with tumors > 50 mm had nearly identical BCSM rates (P = 0.127, P = 0.099 and P = 0.370 for 51-60 mm, 71-80 mm and > 80 mm tumors, respectively), whereas BCSM was positively correlated with tumors < 51 mm.

CONCLUSIONS

The observation of identical HRs for BCSM among patients with ER+ and PR+ tumors >50 mm underscores the importance of individualized treatment. Our findings may contribute to a better understanding of breast cancer biology.

摘要

背景与目的

肿瘤大小的预后价值存在差异。我们旨在描述肿瘤大小与激素受体(HoR)状态之间的相互作用,以确定乳腺癌特异性死亡率(BCSM)。

方法

我们使用监测、流行病学和最终结果(SEER)登记处的数据,识别出1990年至2010年间被诊断为浸润性乳腺癌的328870名女性患者。主要研究变量包括肿瘤大小、联合HoR状态及其相应关系。采用Kaplan-Meier法和带有交互项的校正Cox比例风险模型。

结果

多变量分析显示肿瘤大小与HoR状态之间存在显著交互作用(P < 0.001)。以61 - 70mm大小的肿瘤作为雌激素受体阴性(ER-)和孕激素受体阴性(PR-)疾病的参考,几乎所有类别中,BCSM的风险比(HR)均随肿瘤大小增加而升高。然而,在雌激素受体阳性(ER+)和孕激素受体阳性(PR+)组中,肿瘤>50mm的患者BCSM率几乎相同(51 - 60mm、71 - 80mm和>80mm肿瘤的P值分别为0.127、0.099和0.370),而BCSM与<51mm的肿瘤呈正相关。

结论

ER+和PR+且肿瘤>50mm的患者中BCSM的HR相同,这一观察结果强调了个体化治疗的重要性。我们的发现可能有助于更好地理解乳腺癌生物学。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e389/4673215/d7c1ecfc48b1/oncotarget-06-22985-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验